CELCHealthcare · BiotechnologyThe 12 Wall Street analysts covering Celcuity, Inc. hold a median 12-month price target of $157 — +160.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Celcuity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (87): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CELC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +160.4% from it.
Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | Needham | Maintains | Buy | $140 → $134 |
| 17 Sept 2026 | JP Morgan | Initiates | Overweight | $157 |
| 17 Sept 2026 | JP Morgan | Initiates | Overweight | — |
| 17 Aug 2026 | Citizens | Reiterates | Market Outperform | $177 |
| 17 Aug 2026 | Citizens | Reiterates | Market Outperform | — |
| 17 Aug 2026 | Guggenheim | Maintains | Buy | $165 → $175 |
| 17 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 14 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $155 |
| 14 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2026 | Needham | Maintains | Buy | — |
| 14 Aug 2026 | Needham | Maintains | Buy | $157 → $140 |
| 14 Aug 2026 | Stifel | Maintains | Buy | — |
| 14 Aug 2026 | Stifel | Maintains | Buy | $175 → $150 |
| 15 July 2026 | Citizens | Maintains | Market Outperform | — |
| 15 July 2026 | Citizens | Maintains | Market Outperform | $160 → $177 |
| 15 July 2026 | HC Wainwright & Co. | Maintains | Buy | $145 → $155 |
| 15 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 June 2026 | Craig-Hallum | Maintains | Buy | — |
| 3 June 2026 | Craig-Hallum | Maintains | Buy | $189 → $171 |
| 3 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CELC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, Celcuity, Inc. returned +20.5% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 99% of US stocks
Cheaper than 88% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 1% of US stocks
Higher than 16% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Celcuity, Inc. has a market value of $2.9B and an enterprise value of $3.1B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$226.5M.
Diluted earnings per share, trailing twelve months: $−4.30.
Free cash flow in the twelve months to 30 June 2026: −$192.3M, after $271K of capital spending.
Trailing P/E: −15.8×; forward P/E: −748.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Celcuity, Inc. employs 155 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Celcuity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research added Celcuity (CELC) to its Zacks Rank #5 (Strong Sell) List on October 14, 2026, alongside ADDYY and CNL.
Why it matters — CELC watchers may note the stock’s inclusion in Zacks’ Strong Sell list.
Celcuity announced that a late-breaking rapid oral presentation and three poster presentations featuring data from its clinical trials of gedatolisib will be presented at the ESMO Congress 2026 in Madrid, Spain, October 23-27. The presentations cover subgroup analyses from the VIKTORIA-1 trial in HR+/HER2- advanced breast cancer and from a Phase 1b trial of gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Why it matters — Presentations at a major oncology congress could increase visibility for Celcuity's gedatolisib clinical data among researchers and the broader oncology community.
Celcuity, Inc. announced the appointment of David Gryska to its Board of Directors. Mr. Gryska brings decades of strategic and financial leadership experience to the board.
Why it matters — A CELC watcher would care because adding an experienced financial and strategic leader to the board could strengthen the company's governance and oversight.
Celcuity's stock rose on Wednesday following the FDA's July approval of Revtorpyk, its breast cancer treatment.
Why it matters — The FDA approval of Celcuity's breast cancer treatment mark a significant product milestone for the company.
Celcuity announced that REVTORPYK (gedatolisib) is now commercially available in the United States for eligible patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation following progression on endocrine therapy in the metastatic setting. The therapy is the first and only FDA-approved agent that inhibits all class I PI3K isoforms and both mTOR complexes.
Why it matters — This marks the commercial launch of Celcuity's first FDA-approved therapy, a key milestone as the company transitions from development to commercialization.
The 12 Wall Street analysts covering Celcuity, Inc. have a median 12-month price target of $157, with estimates ranging from $130 to $177. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Celcuity, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Celcuity, Inc. 29 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Celcuity, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (87 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +160.4% from the last close, and Ticker Nerd's factor model ranks Celcuity, Inc. 29 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Celcuity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $130 to $177 over the next 12 months.
Celcuity, Inc. returned +20.5% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications.
The most recent item we track (Zacks Investment Research, 14 Oct 2026): "New Strong Sell Stocks for October 14th". Zacks Investment Research added Celcuity (CELC) to its Zacks Rank #5 (Strong Sell) List on October 14, 2026, alongside ADDYY and CNL.
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s current work centers on cancer treatments that act on the PAM pathway, including its lead therapeutic candidate gedatolisib, which is being developed for advanced breast cancer and metastatic castration-resistant prostate cancer. Celcuity also operates a cellular analysis platform used to identify abnormal signaling activity in tumors and help guide the development of precision oncology therapies. Its business is concentrated in oncology drug development, with programs aimed at patients whose cancers are driven by specific molecular pathways. Headquartered in Minneapolis, Minnesota, Celcuity is positioned as a research-driven biotech company working across therapeutic development and biomarker-based cancer analysis.
CEO Mr. Brian F. Sullivan · 155 employees · United States · https://www.celcuity.com
